A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

  • End date
    Apr 30, 2023
  • participants needed
  • sponsor
    Kodiak Sciences Inc
Updated on 30 July 2021


This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)


This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with visual impairment due to treatment-nave neovascular (wet) age-related macular degeneration (wAMD)

The primary endpoint will be assessed at Week 40; additional secondary endpoints for efficacy will be assessed by visit over time

Condition Wet Age Related Macular Degeneration
Treatment Aflibercept, Sham Procedure, KSI-301
Clinical Study IdentifierNCT04964089
SponsorKodiak Sciences Inc
Last Modified on30 July 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent prior to participation in the study
Treatment-nave choroidal neovascularization (CNV) secondary to AMD
BCVA ETDRS score between 83 and 25 letters, inclusive, in the Study Eye
Decrease in vision in the Study Eye determined by the Investigator to be primarily the result of wAMD
Other protocol-specified inclusion criteria may apply

Exclusion Criteria

BCVA of hand motion or worse in the non-Study Eye or non-physical presence of a non-Study Eye (i.e., monocular)
Active or suspected ocular or periocular infection or inflammation
CNV secondary to other causes in the Study Eye
Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study
Uncontrolled glaucoma in the Study Eye
Significant media opacities, including cataract, in the Study Eye that might interfere with visual acuity, assessment of safety, OCT or fundus photography
Cataract in the Study Eye that in the judgment of the Investigator is expected to require surgical extraction within 12 months of screening
Women who are pregnant or lactating or intending to become pregnant during the study
Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event
History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product
Uncontrolled blood pressure defined as a systolic value 180 mmHg or diastolic value 100 mmHg while at rest
Other protocol-specified exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note